華大基因(300676.SZ)：子公司已與NUPCO簽署修訂協議等等 追加約8280萬美元合同金額
格隆匯 2 月 10日丨華大基因(300676.SZ)公佈，之前公吿披露，公司的全資子公司BGI HEALTH (HK) CO., LTD (中文名華大基因健康科技(香港)有限公司，以下簡稱香港醫學)與沙特阿拉伯王國的NATIONAL UNIFIED COMPANY FOR THEPROCUREMENT OF MEDICINE, DEVICES, AND MEDICAL SUPPLIES (即National Unified Procurement Company，以下簡稱NUPCO)於2020年4月26日籤署了《產品買賣和服務協議》(以下簡稱原合同)。根據合同約定，香港醫學為NUPCO提供新型冠狀(以下簡稱新冠)病毒檢測綜合解決方案，包含檢測儀器和設備、檢測試劑盒及檢測實驗室設計方案等，合同總金額不超過265,183,792美元，合同期限為自合同生效之日起的八個月，經雙方協商一致，合同期限可以延長三個月或更短時間。
截至公吿披露日，公司已累計收到NUPCO支付的上述合同款項金額為164,948,179美元。鑑於對項目雙方組織、交付進度和合作內容的綜合考慮，原合同履行期限需適當延後。近日，香港醫學已與NUPCO簽署了《修訂協議》《補充協議》及《延期協議》(以下將《修訂協議》《補充協議》《延期協議》及原合同合稱為本合同)，相關協議的主要內容如下：
1、履行期限：本合同的履行期限延長至2021年6月25日。
2、合同金額：NUPCO基於項目執行的實際情況，需增加新冠病毒檢測綜合解決方案的採購，本次《延期協議》追加了8280.0565萬美元的合同金額，如實際項目產生費用與此略有變動，雙方應另行書面約定。
此次追加的合同金額為8280.0565萬美元。佔公司2019年度經審計營業收入的19.12%(根據截至2021年2月8日銀行間外匯市場人民幣匯率中間價計算)。該重大合同的履行預計將對公司2021年度或以後年度經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
